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Epidemiological studies of ataxia telangiectasia (AT) families
have suggested that AT heterozygotes could have an increased
cancer risk, especially for breast cancer (BC) in women (Swift et
al, 1987, 1991; Pippard et al, 1988; Børresen et al, 1990; Morrell et
al, 1990; Athma et al, 1996; Stankovic et al, 1998). The estimation
of this increased BC risk assessed from the combined analysis of
available data in 1994 was 3.9 (Easton, 1994). In Europe, two out
of three studies (Pippard et al, 1998; Børresen et al, 1990;
Stankovic et al, 1998) have shown a significant increased risk of
BC but with wide confidence intervals (Stankovic et al, 1988;
Børresen et al, 1990). Moreover, it has been suggested that an
interaction between AT heterozygosis and ionizing radiation expo-
sures could be involved in the increase in BC risk (Swift et al,
1991). However, no data have been published that sustain this
hypothesis. The gene for AT (ATM) was identified in 1995
(Savitsky et al, 1995), allowing the identification of ATM
heterozygotes in families with an AT-affected child, through segre-
gation of AT-linked haplotypes. Thus an epidemiological study of
cancer risks associated with AT heterozygosis collecting informa-
tion on ionizing radiation exposures has been performed in France.
In the present paper, BC relative risk estimation in AT heterozy-
gotes within AT children families is presented.
DATA COLLECTION AND METHODS
A family study of the AT children population was carried out in
France from June 1994 to February 1997. AT children were
recruited by paediatricians who have been surveying this popula-
tion since early childhood and cytogeneticists who have
contributed to their disease diagnosis. AT children were eligible if
their family was living in France at the time of the study. For each
participant who signed a consent form, a blood sample was taken;
and a questionnaire was administrated by a physician to all adult
relatives. A blood or a buccal cell sample was taken from the AT
children and their siblings with parental agreement.
Demographic characteristics (gender, date of birth and, if
deceased, age at death and cause of death) and the occurrence of
BC and any other cancer, including age at diagnosis and places of
medical care were collected from first-degree (parents and siblings
of AT child), second-degree (uncles, aunts and grandparents) and
third-degree (granduncles and -aunts, and great-grandparents,
cousins of AT child) relatives. Epidemiological data on first- and
second-degree relatives aged 18 years or over concerned medical
history, exposure to medical and professional radiation and
detailed reproductive factors for females.
All contacted families, with the exception of one, consented to
participate. Thirty-four French families were recruited. AT chil-
dren were aged from 3 to 32 years. Eighteen of 29 breast malig-
nancies reported in families could be confirmed by pathological
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records and, in all of those, there was complete agreement between
the case report and the pathological record.
Genotyping at the AT locus has been performed studying seven
polymorphic microsatellite markers, six of which are flanking –
two centromeric (D11S1817, D11S1819), four telomeric
(D11S1778, D11S1294, D11S2180, D11S2178) and one intra-
genic (D11S2179). These loci have been selected in view of the
maps previously reported (Savitsky et al, 1995; Laake et al, 1997),
encompassing a region of approximately 2 megabases. Haplotypes
were constructed from the observed segregation of the multiple,
closely linked markers in the extended families assuming a
minimum number of genetic recombinants. The attribution of the
AT heterozygote status was based on the presence of one of the
haplotypes of the affected child, or children, of the family. Given
the small genetic distance between the markers and the ATM gene
and the elevated frequency of heterozygozity (66%) at the studied
loci in our sample, the risk of misleading attribution of the ATM
heterozygosis (ATM het) status was toward the null.
Where ATM het status was not determined by molecular
approach, the a priori probability that the individual with the
undetermined status shares AT mutation with their closest ATM
obligate heterozygote relative was calculated. This mixed
approach provided four classes of AT children relatives: ATM
obligate, 0.5 ATM and 0.25 ATM heterozygotes, and ATM
obligate non-heterozygotes. The a priori probability of AT chil-
dren siblings for whom there were no DNA sample equals 0.66
and concerns a small number of AT children relatives. Thus, in
order to limit the number of classes they were included in the 0.5
ATM heterozygotes category.
Relatives of AT children were considered at risk from the date
of their conception since ATM het status is defined from this
moment. However, as the French incidences of cancers were avail-
able from age 25 years, the relatives of AT children were consid-
ered at risk from 25 years of age to either age at interview or age at
death for the non-affected-by-BC subjects, or age at diagnosis for
the affected-by-BC subjects. When age at diagnosis of BC was
unknown, age at death was used. The relative risk (RR) of BC
association with ATM het status was assessed by the ratio of the
observed number of BC cases (O) and the expected number of BC
cases (E) in the AT families (Breslow and Day, 1987). The calcu-
lation of the expected number of BC cases was performed from the
French estimated incidences of BC between 1978 and 1987
(Benhamou et al, 1990; De Vathaire et al, 1996) per 5-year age
band using the Fortran program PYRS (Coleman et al, 1986). The
RR 95% confidence interval (CI) was calculated as proposed by
Breslow and Day (1987).
RESULTS
The 34 families included 1429 persons with a mean number of 42
persons per family (s.d. = 19). DNA samples from 401 individuals
were studied. In addition, classification of an extra 412 individuals
as ATM obligate heterozygotes or ATM obligate non-heterozy-
gotes was made possible by the mixed approach. The AT children
siblings for whom there was no DNA sample were very few (12
Table 1 ATMheterozygosis (ATM het) status repartition among female relatives of the 34 families
A priori probability approach Mixed approach
ATM het status No. of females (%) No. of females (%) Mean age (s.d.) Person-years
Obligate 40 (5.6) 115 (16.2) 44.2 (19.5) 5079
50% 195 (27.3) 201 (28.3) 45.2 (26.6) 9085
25% 344 (48.2) 107 (15.1) 48.5 (23.5) 5192
12.5% 117 (16.4) –
Obligate non 18 (2.5) 288 (40.5) 46.8 (25.4) 13468
All females 711 711 46.2 (24.6) 32823
s.d. = standard deviation.
Table 2 BC risk according to ATM het status among female relatives of the
34 families
Mixed approach
ATM het status O E O/E 95% CI
Obligate 9 2.71 3.32 (1.75–6.38)
50% 5 6.24 0.80 (0.33–1.92)
25% 3 3.42 0.88 (0.28–2.73)
Obligate non 11 9.26 1.19 (0.66–2.15)
O = observed number of BC cases; E = expected number of BC cases.
Table 3 BC risk according to ATM het status and age among female relatives of the 34 families
Age of female relatives ≤ 44 years Age of female relatives ³ 45 years
ATM Het status O E O/E 95% CI O E O/E 95% CI
Obligate 5 1.10 4.55 (1.89–10.9) 4 4.61 2.48 (0.93–6.61)
50% 0 1.64 0.00 – 5 4.60 1.09 (0.45–2.62)
25% 2 0.99 2.02 (0.51–8.08) 1 2.44 0.41 (0.06–2.91)
Obligate non 2 2.60 0.77 (0.19–3.08) 9 6.66 1.35 (0.70–2.59)
O = observed number of BC cases; E = expected number of BC cases.1044 N Janin et al
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out of 44 with a mean age of 17 years), and they were included in
the 0.5 ATM heterozygotes category. Among the 1429 persons, 29
BC cases had been diagnosed between 1943 and 1996. All cases
with the exception of one were female, that is 28 female cases. Ten
BC cases were ATM heterozygotes, 11 were not ATM hetero-
zygotes. For the remaining eight BC cases, the ATM status was
uncertain with an a priori probability of 0.5 for five and 0.25 for
three. Among the 34 families, at least one BC occurred in 20 fami-
lies. In 14 families only one BC case occurred, in four families two
BC cases occurred, in one family three cases, and in another
family four cases of BC occurred. The male case was ATM
heterozygote with a BC diagnosed in 1972 at 55 years of age.
The age-range of female BC cases at diagnosis was 35–97 years.
Among obligate ATM heterozygote female BC cases, diagnoses
occurred between 1969 and 1995. Among the others, ATM het
status female BC cases, 16 were diagnosed between 1943 and
1995, three had an unknown date of diagnosis, and thus year of
their death was used. The three BC cases with an unknown date of
diagnosis died at 35, 55 and 70 years respectively, their respective
ATM het status is 0.25, 0 and 0.5.
Female relatives of the 34 families are described in Table 1
according to ATM het status comparing the a priori probability
approach to the mixed approach (i.e. haplotype study or a priori
probability for those whose het status was undetermined by molec-
ular approach). The obvious interest of the mixed approach is an
increase by three of the obligate ATM heterozygote number, but also
an increase by 16 of the obligate non-ATM heterozygote number.
The mean age of the women across ATM het status is similar.
In Table 2, the BC relative risks according to ATM het status
among the female relatives are shown. A significant increased risk
of BC is found among obligate ATM heterozygotes with a point
estimate of 3.32 and a 95% CI of 1.75–6.38 (P = 0.002). A slight
non-significantly increased BC risk is found among obligate non-
ATM heterozygotes (O/E = 1.19, IC95% = 0.66–2.15). The BC risk
among other ATM het status groups are not significant with similar
point estimates (0.5 class: O/E = 0.80, IC95% = 0.33–1.92; 0.25
class: O/E = 0.88, IC95% = 0.28–2.73).
In Table 3, the BC relative risks are calculated according to
ATM het status and age of the female relatives. Among female
relatives with an age equal to or less than 44 years, a significant
increase risk of BC is found among obligate ATM heterozygotes
with a point estimate of 4.55 and a 95% CI of 1.89–10.9 (P =
0.005). A non-significant decrease BC risk is found among
obligate non-ATM heterozygotes (O/E = 0.77, IC95% = 0.19–3.08).
Among female relatives with an age equal to or more than 45
years, a statistically borderline increase risk of BC is found among
obligate ATM heterozygotes with a point estimate of 2.48 and a
95% CI of 0.93–6.61 (P = 0.08). A non-significant increase BC
risk is found among obligate non-ATM heterozygotes (O/E = 1.35,
IC95% = 0.70–2.59). The BC risk among the other ATM het status
groups remains non-significant when taking age into account with
variable point estimates and wide confidence intervals (0.5 class:
among females ≤ 44 years, zero observed BC case, among females
³ 45 years O/E = 1.09, IC95% = 0.45–2.62; 0.25 class: among
females  ≤ 44 years, O/E = 2.02, IC95% = 0.51–8.08; among females
³ 45 years O/E = 0.41, IC95% = 0.06–2.91).
DISCUSSION
The finding of this study is in agreement with the increased BC
risk previously detected among ATM heterozygotes (Swift et al,
1987, 1991; Pippard et al, 1988; Børresen et al, 1990; Morrell et al,
1990; Athma et al, 1996). The estimated BC relative risk of 3.32 is
consistent with Athma et al’s (1996) estimate (RR = 3.8) and
Easton’s (1994) combined estimate (RR = 3.9). The point estimate
of BC risk appears higher among female relatives less than 44
years of age than among those more than 45 years of age. This
result cannot be affected by a possible misclassification of the
three BC cases with an unknown age at diagnosis, none of them
being ATM heterozygotes. This result is the opposite to that of
Athma et al’s (1996) and FitzGerald et al’s findings (1997).
Indeed, FitzGerald et al (1997) did not find evidence for an
increase frequency of ATM heterozygotes among women with
early onset of BC. However, let us note that given the low
estimated frequency of ATM carriers, they had little chance of
detecting an increase risk (40% chance for a fourfold increase in
risk and 6% for a twofold increase) (Bebb et al, 1997; Bishop and
Hopper, 1997). In the same way, Athma et al (1996) found an
increased risk of BC for ATM heterozygotes and even higher at
older ages (60 or older).
A possible bias in family recruitment due to a higher participa-
tion of families with a BC may be suggested. Indeed, the slight
non-significant increase of BC risk among obligate non-ATM
heterozygotes may reflect a possible ascertainment bias. However,
the BC higher risk among the obligate ATM heterozygotes
remains, even when adjusted (i.e. adjusted RR » 2.8).
The slight non-significantly decreased BC risk found among the
groups at 50% or 25% risk to be ATM carriers could reflect a bias
towards a higher proportion of known heterozygosis status for BC
cases than for the non-BC cases leading to an overestimation of
obligate ATM carriers BC risk. Indeed, 29% (eight out of 28) of
BC cases have an uncertain ATM carrier status against 44% of
non-BC cases (300 out of 683). However, the observed decreased
BC risk is not statistically significant and the obligate ATM
carriers BC risk may not be dramatically overestimated.
The declared BCs among families have been verified for more
than the majority. Moreover, BC has been found to be reported
with great accuracy in numerous studies. In particular, Theis et al
(1994) found concordance of 99% between case report and the
pathological report. However, the non-affected-by-cancer individ-
uals in families have not been checked because of lack of a
national French registry, although it has been estimated that 98%
of negative families’ history were correct (Aitken et al, 1995). A
poor sensitivity of self-reported family history of BC (i.e. under
reporting) may lead to an under-estimate of the BC relative risk
across heterozygosis status classes.
The calculations of expected numbers of BC are known to be
sensitive to the reference population used. Because national inci-
dence data are not available in France, estimated incidences of BC
between 1978 and 1987 were used as the reference population in
this study (Benhamou et al, 1990; De Vathaire et al, 1996). This
might induce an over-estimate of the expected numbers of BC
among exposed women before 1978 (mostly grandmothers, grand-
aunts and great-grandmothers of AT children) and an under-
estimate of this number among exposed women after 1987 (mostly
mothers and aunts) since the BC incidence rate has been increasing
in West European countries for a number of decades (Parkin et al,
1993). This may not explain the increased risk of BC among all of
obligate AT heterozygotes but might partially explain the observed
difference in BC relative risk between younger and older female
relatives. For this reason, comparison between the BC relative
risks of young and old ATM obligate heterozygote females is moreBreast cancer risk and the ATM gene 1045
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suitable, adjusted on respective obligate non-ATM heterozygotes
BC relative risks. Thus, an observed difference in the point esti-
mates remains with a BC risk of 5.9 among the younger ATM
obligate heterozygote female relatives and 1.8 among the olders.
Since neither shows convincing difference in RR estimated by age
bands given the RR confidence intervals, other studies are needed
to clarify this point.
Although still imprecise, the detected increased risk may have a
point estimate of about 3, which is only a little higher than clas-
sical reproductive risk factors (i.e. a young age at menarche, a
nulliparity or a late age at first childbirth etc) and similar to the
risk associated with a family history of BC among first-degree
relatives (Kelsey and Horm-Ross, 1993). However, the previous
suggestion that the ATM heterozygotes would be highly ionizing-
radiation sensitive (Swift et al, 1987) is still unconfirmed. Indeed,
studies on highly clinical-radiosensitive BC patients did not show
evidence for an elevated ATM heterozygote rate (Appleby et al,
1997; Shayeghi et al, 1998). Thus it does not appear necessary,
so far, to subject women with ATM het status to any different
screening program which is not already available to women with a
first-degree relative affected by BC. Nevertheless, further studies
are needed for assessing the BC risk among ATM heterozygotes
according to their past ionizing-radiation exposures. Indeed, such
studies may allow us to improve the understanding of the under-
lying mechanisms involved in the observed increased BC risk
among ATM heterozygotes.
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